Introduction
============

Endoscopic ultrasound (EUS) guided fine-needle aspiration (EUS-FNA) is the mainstay for tissue acquisition for evaluation of lesions adjacent to the digestive tract, including pancreas, liver, adrenals, lymph nodes, and gastrointestinal subepithelial tumors [@JR664-1] [@JR664-2] [@JR664-3] [@JR664-4] [@JR664-5]. Despite its widespread adoption, the diagnostic yield of FNA is highly variable, as is evident with solid pancreatic neoplasms, where reported sensitivities range from 64 % to 95 %, specificities range from 75 % to 100 %, and diagnostic accuracies range from 78 % to 95 % [@JR664-6]. The reported diagnostic accuracy for other lesions such as mediastinal masses and gastrointestinal tract stromal tumors (GISTs) is even lower [@JR664-7] [@JR664-8]. This variation in diagnostic utility is dependent on a number of factors, including lesion location, the availability of cytology staff for rapid onsite evaluation (ROSE), the skill and experience of the endosonographer, and the size and type of needle selected for tissue acquisition. An important limitation of EUS-FNA is that it does not provide core tissue specimens with preserved architecture, which is required for immunohistochemical staining and histologic diagnosis of conditions such as lymphoma, GIST, and autoimmune pancreatitis [@JR664-9] [@JR664-10] [@JR664-11].

In an effort to overcome some of the limitations of EUS-FNA, a dedicated EUS core biopsy needle (19G Trucut needle) was developed over a decade ago. However, this first generation fine-needle biopsy (FNB) device failed to show superiority over traditional FNA [@JR664-12]. Moreover, the technical failure rate was high, especially when FNB was attempted with an angulated scope position -- such as when working in the duodenum -- due to the stiffness of the device. Consequently, more flexible second generation core biopsy needles have been developed, and are being increasingly used for tissue acquisition. These include ProCore (Cook Endoscopy) needles with a reverse-bevel for tissue acquisition and the recently approved fork-tip (SharkCore, Medtronic Corp.) needles; both are available in 19, 22, and 25 gauges. Core tissue samples obtained with these newer core biopsy needles may improve diagnostic yield, and may potentially obviate the need for ROSE. Studies comparing these second generation core biopsy needles with standard FNA needles have reached different conclusions. Studies from the United States have used ROSE routinely for FNA, but since ROSE is not uniformly available in other parts of the world, most studies conducted outside the United States have not used ROSE. We therefore conducted a systematic review and meta-analysis comparing the diagnostic performance of second generation core biopsy needles with standard FNA needles, specifically analyzing the role of ROSE in such comparisons.

Methods
=======

This systematic review was carried out in accordance with the guidelines of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) [@JR664-13] and meta-analysis of observational studies in epidemiology (MOOSE) [@JR664-14].

Data sources and search strategy
--------------------------------

A systematic search of the literature was conducted by an experienced medical reference librarian (R.N.) with 18 years of experience. The search strategies were developed in Ovid MEDLINE and translated to match the subject headings and keywords for Ovid EMBASE, Cochrane database, and Scopus from inception through 16 June 2016. The following MeSH, Emtree, and keyword search terms were used: "endoscopic ultrasound", "EUS", "fine needle aspiration", "fine needle biopsy", "ProCore", "core biopsy", "fork-tip needle", "SharkCore", "EUS-FNA", and "EUS-FNB". The search accounted for plurals and variations in spelling with the use of appropriate wildcards. Articles were selected for full text review on the basis of their title and abstract. A manual search was conducted through the bibliographies of the retrieved publications to increase the yield of potentially relevant articles. All results were downloaded into EndNote 7.5 (Thompson ISI ResearchSoft, Philadelphia, Pennsylvania, United States), a bibliographic database manager; any duplicate citation was identified and removed.

Inclusion and exclusion criteria
--------------------------------

Two authors (M.K.I. and B.A.) searched for original articles using predetermined inclusion criteria. To meet the inclusion criteria, studies had to be randomized trials or observational studies (cohort or case -- control design) and compared the second generation core biopsy needles (ProCore and SharkCore) with standard FNA needles of any gauge using EUS for sampling solid lesions. We restricted our search to studies that included patients over the age of 18 years and included at least one of the following as outcome measures: diagnostic adequacy, diagnostic accuracy, optimal core histological samples, and mean number of needle passes required to establish the diagnosis. Studies may or may not have used ROSE. Studies were excluded if they did not directly compare second generation core biopsy needles with standard FNA needles, included data on first generation 19G Trucut biopsy needles, or if data were not reported as one of the aforementioned outcomes. Studies were also excluded if they reported experimental data on animals or if data were included in a more recently published study in which case the most recent study was included. Only studies published in English in peer reviewed journals were included in the analysis. Data presented as abstracts were excluded, as there is a discrepancy between full publications and published abstracts [@JR664-15] [@JR664-16].

Study selection and data extraction
-----------------------------------

Two reviewers (M.A.K. and M.K.I.) independently assessed the eligibility of the identified studies, collected information to assess the methodological validity of each included study, and extracted data using structured data extraction forms. Any disagreement between the reviewers was to be discussed with a third reviewer (T.H.B.), with an agreement to be reached by consensus. Extracted data included study design, country and year of study, patient demographics, location of lesion, presence or absence of onsite pathologist, follow-up period, diagnostic adequacy, diagnostic accuracy, optimal quality histological core procurement, mean number of passes required to obtain the diagnosis, and, wherever available, procedure details including needle gauges, application of suction and fanning techniques.

Quality assessment of included studies
--------------------------------------

Quality assessment was done by two reviewers (M.K.I and M.A.K.) independently using the Newcastle Ottawa Scale (NOS) for observational studies and the Cochrane tool for assessing risk of bias for randomized trials. The Newcastle Ottawa scale measures quality in the three parameters of selection, comparability, and exposure/outcome, and allocates a maximum of 4, 2, and 3 points, respectively. High-quality studies are scored greater than 7 on this scale, and moderate-quality studies, between 5 and 7. The Cochrane tool for quality assessment checks for selection bias, performance bias, detection bias, attrition bias, and reporting bias. Any discrepancy between reviewers for quality assessment was discussed with a third reviewer (I.G.) with agreement reached by consensus.

Data synthesis and statistical analysis
---------------------------------------

We assessed the following four outcomes of interest: (1) diagnostic adequacy, defined as the ability to procure cytological and/or histological samples adequate for interpretation; (2) diagnostic accuracy, defined as the ability to make a definitive diagnosis based on cytological aspirate and/or core tissue; (3) optimal core histological tissue, defined as samples with high cellularity and quality enabling appropriate core assessment in terms of tissue architecture; (4) number of passes required to establish a diagnosis.

Risk ratios (RR) were calculated for categorical outcomes of interest (diagnostic adequacy, diagnostic accuracy, and optimal core histological tissue) comparing the core biopsy needles with standard FNA needles. Standard mean differences (SMD) were calculated for continuous variables (number of passes to obtain diagnosis) comparing the two types of needles. Subgroup analyses evaluating the same variables (apart from number of passes required to establish diagnosis) for pancreatic lesions exclusively were also conducted. These outcome variables were pooled one at a time and a meta-analysis was performed using either a fixed effect model or Der-Simonian and Laird random effects model [@JR664-17] depending on the presence or absence of significant heterogeneity, respectively, and corresponding forest plots constructed. Heterogeneity across the studies was assessed using the Cochran Q test and *I* ^2^ statistics. A *P* value of \< 0.1 for the Cochran Q test was defined as indicating the presence of heterogeneity. *I* ^2^-values of 0 -- 40, 30 -- 60, 50 -- 90, and 75 -- 100 % were reflective of low, moderate, substantial, and considerable heterogeneity, respectively [@OR664-18]. Publication bias was assessed through funnel plots and Egger's test for asymmetry. Meta-regression was conducted to explore heterogeneity and specifically the effect of onsite pathology was evaluated in these outcomes to explain any differences in results. When meta-regression showed a trend or significant results, scatterplots were constructed to graphically present the data. All statistical analyses were conducted using Comprehensive Meta-analysis software (version 3.0; Biostat; Englewood, New Jersey, United States).

Results
=======

Search strategy yield, study characteristics, and quality assessment
--------------------------------------------------------------------

The search strategy identified 3067 publications, of which 481 were removed as duplicates and a further 2501 were excluded as being ineligible based on title and abstract review. Backward snowballing of 85 retrieved studies did not reveal any additional study meeting our inclusion criteria. After full text review of these 85 articles, 70 studies were removed, including studies not having comparative data for standard FNA needles with second generation FNB needles, review articles, and studies not evaluating any of the four main outcome measures listed in the inclusion criteria. Consequently, 15 studies [@JR664-19] [@JR664-20] [@JR664-21] [@JR664-22] [@JR664-23] [@JR664-24] [@JR664-25] [@JR664-26] [@JR664-27] [@JR664-28] [@JR664-29] [@JR664-30] [@JR664-31] [@JR664-32] [@JR664-33] with 1024 patients were included in the main analysis of which four were randomized trials [@JR664-19] [@JR664-22] [@JR664-23] [@JR664-24] and 11 were observational studies [@JR664-20] [@JR664-21] [@JR664-25] [@JR664-26] [@JR664-27] [@JR664-28] [@JR664-29] [@JR664-30] [@JR664-31] [@JR664-32] [@JR664-33]. The search strategy is summarized in [Fig. 1](#FI664-1){ref-type="fig"}. Seven studies [@JR664-20] [@JR664-23] [@JR664-25] [@JR664-26] [@JR664-27] [@JR664-28] [@JR664-33] used a crossover design in which both needles were used in all patients, while eight studies [@JR664-19] [@JR664-21] [@JR664-22] [@JR664-24] [@JR664-29] [@JR664-30] [@JR664-31] [@JR664-32] used either a standard FNA needle or a core biopsy needle in each patient. Seven studies [@JR664-19] [@JR664-23] [@JR664-24] [@JR664-25] [@JR664-28] [@JR664-29] [@JR664-30] included pancreatic lesions exclusively while one study [@JR664-22] included subepithelial lesions exclusively. A total of 700 solid pancreatic lesions were included in the analysis. Rapid onsite pathology evaluation was available in all of the eight studies [@JR664-19] [@JR664-21] [@JR664-25] [@JR664-26] [@JR664-28] [@JR664-31] [@JR664-32] [@JR664-33] conducted in the United States, whereas it was only available in one non-U.S. study [@JR664-24]. Two studies [@JR664-32] [@JR664-33] used the fork-tip or SharkCore needle for FNB, while the rest of the 13 studies used the ProCore needle. Study characteristics and patient demographics are presented in [Table  1](#TB664-1){ref-type="table"} and [Table  2](#TB664-2){ref-type="table"}.

![ PRISMA flow chart (study selection process).](10-1055-s-0043-101693-i664ei1){#FI664-1}

###### Characteristics of included studies.

  **Study, year and country**               **Design**         **Location of lesions**                                                     **Inclusion criteria**                                                                                      **Exclusion criteria**                                                                                                                        **n**   **Males**   **Age, years**   **ROSE**   **Suction**   **Fanning**   **Follow-up**
  ----------------------------------------- ------------------ --------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- ------- ----------- ---------------- ---------- ------------- ------------- ---------------
  Bang, 2012 (USA) [@JR664-19]              Randomized trial   Pancreas                                                                    All patients referred for solid pancreatic lesions on CT scan                                               Cystic pancreatic lesions, coagulopathy, lesions not seen on EUS                                                                              56      31          65               Yes        No            Yes           6 months
  Hucl, 2013 (India) [@JR664-20]            Prospective        Pancreas & lymph nodes                                                      Consecutive patients with pancreatic masses or peri-intestinal nodes                                        Lesion not seen on EUS                                                                                                                        145     80          48               No         Yes           No            6 months
  Witt, 2013 (USA) [@JR664-21]              Retrospective      Pancreas, gastric, mediastinal and pelvic nodes                             First 18 patients undergoing EUS guided FNB for various lesions. Site matched controls undergoing EUS-FNA   NR                                                                                                                                            36      NR          NR               Yes        Yes           No            3.3 months
  Kim, 2014 (Korea) [@JR664-22]             Randomized trial   Subepithelial lesions                                                       Hypoechoic mass in submucosa and/or proper muscle layers, \> 2 cm in size                                   Tumors not located in submucosa and/or proper muscle layers, cystic lesion, overlying vessel, platelet \< 50 000, PT \> 50 %, lipoma on EUS   22      10          56.3             No         Yes           No            NR
  Vanbiervliet, 2014 (France) [@JR664-23]   Randomized trial   Pancreas                                                                    Pancreatic mass on CT scan, dilated CBD and or dilated PD                                                   Cystic lesions, uncorrectable coagulopathy, pregnancy                                                                                         80      49          67.1             No         Yes           Yes           6.4 months
  Lee, 2014 (Korea) [@JR664-24]             Randomized trial   Pancreas                                                                    Solid pancreatic mass on CT or MRI, age \> 18 years                                                         Cystic mass, INR \> 1.5, platelets \< 80 000                                                                                                  116     77          64.9             Yes        Yes           No            6 months
  Strand, 2014 (USA) [@JR664-25]            Prospective        Pancreas                                                                    Age 18 -- 90 years, solid pancreatic mass on CT scan                                                        Cystic lesion, no mass seen on EUS, uncorrectable coagulopathy                                                                                32      13          67.7             Yes        Yes           No            NR
  Lin, 2014 (USA) [@JR664-26]               Prospective        Pancreas, lymph nodes, gastric, mediastinal nodes, liver lesions            All patients referred for EUS guided biopsy underwent both FNA and FNB                                      Core biopsy not performed if cystic lesions, \< 1 cm lesion, overlying vascular structures precluding biopsy                                  26      25          66.8             Yes        Yes           NR            12 months
  Mavrogenis, 2015 (Belgium) [@JR664-27]    Prospective        Pancreas, lymph nodes                                                       All patients \> 18 years old with pancreatic lesions or lymphadenopathy referred for EUS sampling           Cystic lesion, age \< 18 years, pregnancy, INR \> 1.5, platelet \< 50 000                                                                      28      9          69 (med)         No         Yes           No            7 months
  Berzosa, 2015 (USA) [@JR664-28]           Retrospective      Pancreas                                                                    Patients with solid pancreatic lesions on CT scan undergoing EUS sampling                                   NR                                                                                                                                             61     35          61               Yes        NR            No            6 months
  Alatawi, 2015 (France) [@JR664-29]        Prospective        Pancreas                                                                    Solid pancreatic tumors \> 2 cm size on CT or MRI                                                           Cystic lesions, patients with biliary stents                                                                                                  100     63          68.4             No         Yes           Yes           NR
  Yang, 2015 (Korea) [@JR664-30]            Retrospective      Pancreas                                                                    Solid pancreatic lesions in consecutive patients undergoing EUS                                             NR                                                                                                                                             76     35          62.4             No         Yes           Yes           6 months
  Dwyer, 2016 (USA) [@JR664-31]             Retrospective      Pancreas, gastric and colon submucosal mass, pelvic and perirectal masses   All EUS guided biopsies of solid intraabdominal masses                                                      NR                                                                                                                                             58     32          63               Yes        NR            NR            NR
  Kandel, 2016 (USA) [@JR664-32]            Retrospective      Pancreas, liver, subepithelial lesions, lymph nodes                         Consecutive patients undergoing EUS-FNB were matched with random controls undergoing EUS-FNA ratio of 1:3   NR                                                                                                                                            156     84          66               Yes        NR            NR            NR
  Rodrigues-Pinto, 2016 (USA) [@JR664-33]   Retrospective      Pancreas, lymph nodes, submucosal lesions                                   NR                                                                                                          NR                                                                                                                                             33     15          65               Yes        Yes           NR            NR

NR, not reported; CBD, common bile duct; PD, pancreatic duct; INR, international normalized ratio; PT, prothrombin time; EUS, endoscopic ultrasound; FNB, fine-needle biopsy; FNA, fine-needle aspiration; ROSE, rapid onsite evaluation.

###### Outcomes assessed in meta-analysis.

  **Study**                                 **Groups**   **Needle size, G**   **Diagnostic adequacy**   **Diagnostic accuracy**   **Optimal histology cores**   **Mean number (SD) of passes required for diagnosis**   **NOS quality assessment**   **Cochrane tool for risk of bias**                                
  ----------------------------------------- ------------ -------------------- ------------------------- ------------------------- ----------------------------- ------------------------------------------------------- ---------------------------- ------------------------------------ ------------------------ --- -------------------------------------------------------------------------------------------------
  Bang, 2012 (USA) [@JR664-19]              FNAFNB       2222                                           28/2825 /28                                             28/2825 /28                                                                          8/1214 /18                           1.61 (0.88)1.28 (0.54)       High risk of performance bias, low risk for selection, detection, attrition, and reporting bias
  Hucl, 2013 (India) [@JR664-20]            FNAFNB       2222                 127/145125 /145           60/6964 /69               112/139110 /139               51/6959 /69                                             96/139100 /139                                                    2.47 (0.93)1.23 (0.47)   8   
  Witt, 2013 (USA) [@JR664-21]              FNAFNB       2222                 16/1817 /18                                         17/1817 /18                                                                           10/138 /11                                                        2.942.11                 6   
  Kim, 2014 (Korea) [@JR664-22]             FNAFNB       2222                 2/109/12                                            2/109/12                                                                              2/109/12                                                          3.2 (1.3)1.8 (0.9)           High risk of performance bias, low risk for selection, detection, attrition, and reporting bias
  Vanbiervliet, 2014 (France) [@JR664-23]   FNAFNB       2222                                           NRNR                                                    74/8072/80                                                                           70/8056/80                           NRNR                         High risk of performance bias, low risk for selection, detection, attrition, and reporting bias
  Lee, 2014 (Korea) [@JR664-24]             FNAFNB       22 & 2522 & 25                                 NRNR                                                    55/5857/58                                                                           45/5848/58                           NRNR                         High risk of performance bias, low risk for selection, detection, attrition, and reporting bias
  Strand, 2014 (USA) [@JR664-25]            FNAFNB       2222                                           32/3219/27                                              30/329/27                                                                            7/919/27                             2.9 (1.55)1.4 (0.67      4   
  Lin, 2014 (USA) [@JR664-26]               FNAFNB       2222                 NRNR                                                24/2622/26                                                                            NRNR                                                              NRNR                     6   
  Mavrogenis, 2015 (Belgium) [@JR664-27]    FNAFNB       2225                 22/2824/28                15/1916/19                24/2824/28                    17/1917/19                                              24/2822/28                   17/1915/19                           NRNR                     7   
  Berzosa, 2015 (USA) [@JR664-28]           FNAFNB       2522                                           50/6145/61                                              46/6142/61                                                                           NRNR                                 NRNR                     6   
  Alatawi, 2015 (France) [@JR664-29]        FNAFNB       2222                                           45/5050/50                                              42/5045/50                                                                                                                3.28 (1.0)2.59 (0.49)    8   
  Yang, 2015 (Korea) [@JR664-30]            FNAFNB       2225                                           NRNR                                                    37/3834/38                                                                           23/3826/38                           NRNR                     7   
  Dwyer, 2016 (USA) [@JR664-31]             FNA FNB      22 & 2522 & 25       14/1838/49                12/1535/40                12/1837/49                    10/1534/40                                              NRNR                         NRNR                                 3.483.57                 6   
  Kandel, 2016 (USA) [@JR664-32]            FNAFNB       19,22,2519,22,25     108/11437/39                                        NRNR                                                                                  23/6713/37                                                        NRNR                     8   
  Rodrigues-Pinto, 2016 (USA) [@JR664-33]   FNAFNB       22, 2522, 25         NRNR                                                26/3330/33                                                                            NRNR                                                              NRNR                     7   

FNA, fine-needle aspiration; FNB, fine-needle biopsy; NOS, Newcastle Ottawa Scale; NR, not reported; SD, standard deviation.

Quality assessment of four randomized trials [@JR664-19] [@JR664-22] [@JR664-23] [@JR664-24] was done using the Cochrane tool for assessing risk of bias. All of the four trials had a high risk of performance bias as none of the endoscopists was blinded to the type of needle being used. However, cytopathologists analyzing the samples were blinded to the type of needle. The risks of selection bias, detection bias, attrition bias, and reporting bias were found to be low in all of the four trials. The Newcastle Ottawa scale was used for appraising the quality of observational studies. Three studies [@JR664-20] [@JR664-29] [@JR664-32] satisfied the criteria of high quality studies, seven [@JR664-21] [@JR664-26] [@JR664-27] [@JR664-28] [@JR664-30] [@JR664-31] [@JR664-33] were of moderate quality, and one [@JR664-25] was of low quality ([Table  2](#TB664-2){ref-type="table"}).

Meta-analyses
-------------

### Diagnostic adequacy

Ten studies [@JR664-19] [@JR664-20] [@JR664-21] [@JR664-22] [@JR664-25] [@JR664-27] [@JR664-28] [@JR664-29] [@JR664-31] [@JR664-32] with a total of 694 patients evaluated the diagnostic adequacy of the two types of procurement needle. Pooled RR for diagnostic adequacy with 95 % confidence interval (CI) was 0.98 (0.91, 1.06), (Cochran Q test *P* = 0.01, *I* ^2^ = 51 %; [Fig. 2](#FI664-2){ref-type="fig"}). Sensitivity analysis was done after removing the only low quality study [@JR664-25], to obtain a more robust estimate. The adjusted pooled RR with 95 %CI was 1.00 (0.94, 1.07), (Cochran Q test P = 0.14, I2 = 36 %). Six studies [@JR664-19] [@JR664-21] [@JR664-25] [@JR664-28] [@JR664-31] [@JR664-32] had an onsite pathologist available for specimen analysis. We evaluated the effect of onsite pathology by conducting a meta-regression to further explore heterogeneity in our estimate. Although not statistically significant, the absence of onsite pathologist showed a trend of better diagnostic adequacy with FNB in comparison to FNA (Intercept coefficient: -- 0.51, No onsite pathology coefficient: 1.30, P = 0.06). A scatterplot for meta-regression analyzing the effect of onsite pathology is presented in [Fig. 3](#FI664-3){ref-type="fig"}. This signifies that in the absence of ROSE, FNB showed a trend of better diagnostic adequacy. The funnel plot appeared symmetric and Egger's test failed to detect any publication bias (*P* = 0.65, two tailed).

![ Forrest plot for diagnostic adequacy of FNA in comparison to FNB.](10-1055-s-0043-101693-i664ei2){#FI664-2}

![ Scatterplot for meta-regression analysis for onsite pathology in diagnostic adequacy (*P* = 0.06).](10-1055-s-0043-101693-i664ei3){#FI664-3}

Subgroup analysis was conducted evaluating the diagnostic adequacy in pancreatic lesions and seven studies were involved in this analysis. Pooled RR with 95 %CI for diagnostic adequacy of pancreatic lesions was 0.96 (0.86, 1.09), (Cochran Q test *P* = 0.004, *I* ^2^ = 66 %; [Fig. 4](#FI664-4){ref-type="fig"}). Sensitivity analysis was performed after removing the study by Strand et al. [@JR664-25] as it appeared to be an outlier in the estimate. Pooled RR was 1.00 (0.91, 1.11), (Cochran Q test *P* = 0.06, *I* ^2^ = 50 %). To further explore heterogeneity, onsite pathology was evaluated as a source of heterogeneity in meta-regression analysis. The absence of onsite pathology was a significant predictor of heterogeneity and was associated with better diagnostic adequacy of core biopsy needle in comparison to fine-needle aspiration (intercept coefficient = -- 0.56, No onsite pathology coefficient = 1.30, *P* = 0.02). A scatterplot summarizing this meta-regression is shown in [Fig. 5](#FI664-5){ref-type="fig"}. This signifies that, in the absence of ROSE, FNB had better diagnostic adequacy in pancreatic lesions. To summarize, in the absence of an onsite pathologist, the performance of core needle biopsy was relatively better compared to fine-needle aspiration in terms of diagnostic adequacy of pancreatic lesions.

![ Forrest plot for diagnostic adequacy of FNA in comparison to FNB for pancreatic lesions.](10-1055-s-0043-101693-i664ei4){#FI664-4}

![ Scatterplot for meta-regression analysis for onsite pathology in diagnostic adequacy for pancreatic lesions (*P* = 0.02).](10-1055-s-0043-101693-i664ei5){#FI664-5}

### Diagnostic accuracy

A total of 12 studies [@JR664-20] [@JR664-21] [@JR664-23] [@JR664-24] [@JR664-25] [@JR664-26] [@JR664-27] [@JR664-28] [@JR664-29] [@JR664-30] [@JR664-31] [@JR664-33] comprising 791 patients evaluated the diagnostic accuracy of FNB in comparison to FNA. Pooled RR with 95 %CI for diagnostic accuracy was 0.99 (0.95, 1.03), (Cochran Q test *P* = 0.18, *I* ^2^ = 27 %; [Fig. 6](#FI664-6){ref-type="fig"}). Once again the study by Strand et al. [@JR664-25] appeared to be an outlier in the estimate; therefore, we conducted a sensitivity analysis after excluding it. The adjusted RR with 95 %CI was 1.00 (0.96, 1.04), (Cochran Q test *P* = 0.68, *I* ^2^ = 0 %). The funnel plot appeared symmetric and Egger's test for asymmetry was negative (*P* = 0.93, two tailed).

![ Forrest plot for diagnostic accuracy of FNA in comparison to FNB.](10-1055-s-0043-101693-i664ei6){#FI664-6}

Nine studies evaluated the diagnostic accuracy of FNB in comparison to FNA for pancreatic lesions. Pooled RR with 95 %CI was 0.99 (0.90, 1.08), (Cochran Q test *P* = 0.003, *I* ^2^ = 65 %; [Fig. 7](#FI664-7){ref-type="fig"}). After removing Strand et al. [@JR664-25], sensitivity analysis showed pooled RR 1.01 (0.96, 1.05), (Cochran Q test *P* = 0.28, *I* ^2^ = 19 %). On meta-regression analysis, onsite pathology was not a significant predictor of heterogeneity (intercept coefficient = -- 0.43, No onsite pathology = 0.48, *P* = 0.56).

![ Forrest plot for diagnostic accuracy of FNA in comparison to FNB in pancreatic lesions.](10-1055-s-0043-101693-i664ei7){#FI664-7}

### Optimal quality histological core procurement

Nine studies comprising 725 patients compared the two types of needle in their ability to procure optimal histological cores. Pooled RR with 95 %CI for procurement of optimal histological cores was 0.97 (0.89, 1.05), (Cochran Q test, *P* = 0.35, *I* ^2^ = 9.6 %;  [Fig.8](#FI664-8){ref-type="fig"}). The funnel plot appeared symmetric and Egger's test did not detect any publication bias (P = 0.63, two tailed). Six studies compared optimal quality core procurement in pancreatic lesions. Pooled RR with 95 %CI was 0.95 (0.83, 1.09), (Cochran Q test P = 0.13, I2 = 35 %; [Fig. 9](#FI664-9){ref-type="fig"}).

![ Forrest plot for optimal histological core procurement comparing FNA with FNB.](10-1055-s-0043-101693-i664ei8){#FI664-8}

![ Forrest plot for optimal histological core procurement comparing FNA with FNB in pancreatic lesions.](10-1055-s-0043-101693-i664ei9){#FI664-9}

### Number of passes required to establish diagnosis

Seven studies with 449 patients provided comparative data on the mean number of passes required to establish diagnosis with each needle. Pooled standard mean difference (SMD) with 95 %CI was in favor of FNB \[0.93 (0.45, 1.42), (Cochran Q test *P* \< 0.0001, *I* ^2^ = 84 %;[Fig. 10](#FI664-10){ref-type="fig"})\]. Meta-regression analysis was conducted to explore heterogeneity. The absence of onsite pathology was significantly associated with a higher SMD (intercept coefficient = 0.64, No onsite pathology coefficient: 0.68, *P* = 0.03). Meta-regression is summarized in the scatterplot ([Fig. 11](#FI664-11){ref-type="fig"}). Therefore, in the presence of an onsite pathologist, FNA required relatively fewer passes to establish the diagnosis than in the absence of an onsite pathologist. In summary, core needles are superior in establishing the diagnosis with fewer passes irrespective of the presence of onsite pathology. No publication bias was detected by Egger's test of asymmetry (*P* = 0.13).

![ Forrest plot for number of passes required for diagnosis with FNA in comparison to FNB.](10-1055-s-0043-101693-i664ei10){#FI664-10}

![ Scatterplot for meta-regression evaluating effect of onsite pathology on number of passes.](10-1055-s-0043-101693-i664ei11){#FI664-11}

Discussion
==========

EUS-FNA with ROSE is considered to be the gold standard for EUS-guided tissue acquisition in the United States; however, ROSE has not been uniformly incorporated in all centers in the United States and even less so worldwide. The main aim of this meta-analysis was to evaluate diagnostic performance of second generation FNB needles in comparison to FNA and to evaluate the influence of onsite cytopathology in such an estimate.

Major limitations of EUS-FNA are the relatively small amount of tissue obtained and the inability to provide core tissue for histochemical analysis, which is indispensable not only in the diagnosis of certain malignant conditions such as GISTs, and lymphoma but also in diagnosing benign conditions such as autoimmune pancreatitis [@JR664-9] [@JR664-11]. Another drawback of standard FNA is the presumed requirement of ROSE to increase diagnostic yield. As a result, the field continues to search for tissue acquisition alternatives that can allow high diagnostic accuracy without the use of ROSE. One such alternative is the development of core biopsy needles for procuring histological samples. Studies comparing the first generation Trucut biopsy needle with standard FNA failed to establish superiority of core biopsy needles to FNA [@JR664-34] [@JR664-35]. Studies comparing the second generation needles have reached conflicting results. A previous meta-analysis [@JR664-36] of small numbers of studies and patient populations failed to show any difference between the diagnostic performances of FNA in comparison to second generation core biopsy needles; however, they did not specifically address the issue of onsite cytopathology, which is one of the major reasons for the development of core biopsy needles.

Onsite pathology increases the diagnostic performance of EUS-FNA [@JR664-37], but because of its limited availability to tertiary care centers in the United States, this increased diagnostic performance may not be applicable to centers that do not have ROSE. A recent study by Kandel et al. [@JR664-32] showed significantly better histological sample procurement with a fork-tip FNB needle (SharkCore) in comparison with a standard FNA needle (95 % versus 59 %, *P* = 0.01), with fewer passes in favor of FNB (2 versus 4, *P* = 0.001). Likewise, another observational study [@JR664-33] with a crossover design demonstrated that a diagnosis of malignancy was more likely with FNB (72.7 % versus 66.7 %, *P* = 0.003). This study also showed that FNB samples also provided qualitative information such as degree of differentiation in malignancy, metastatic origin, and rate of proliferation in neuroendocrine tumors which were not available with samples procured from standard FNA needles.

In our meta-analysis, diagnostic adequacy was similar for both types of FNB needles for all lesions. However, the analysis was limited by moderate heterogeneity and on meta-regression. A trend towards better diagnostic adequacy with second generation core biopsy needles was seen in the absence of onsite pathology. Likewise, when these two needles were used exclusively for pancreatic lesions, we found no significant difference in diagnostic adequacy. Once again the analysis for only pancreatic lesions was limited by moderate heterogeneity and on meta-regression analysis; onsite pathology was a significant predictor of heterogeneity. The absence of onsite pathology was associated with a significant increase in diagnostic adequacy when core biopsy needles were used. We did not find any difference in diagnostic accuracy and optimal histological core procurement between FNA and core needles for all lesions, and when analyzing only pancreatic lesions. Finally, core biopsy needles required significantly fewer passes to establish the diagnosis compared to standard FNA. This analysis was limited by considerable heterogeneity and onsite pathology was found to be a significant predictor of heterogeneity. In short, standard FNA needles required relatively fewer passes in the presence of onsite pathology compared to absence of onsite pathology.

It is worth noting that while ROSE increases the diagnostic performance of FNA, it also increases direct costs and procedure duration. If similar diagnostic ability can be attained with core biopsy needles, ROSE may not be required for better diagnostic performance. Increased procedure duration translates into higher opportunity costs (costs associated with lost time while awaiting cytological interpretation feedback). Lin et al. [@JR664-26] found that FNB using two needle passes had similar diagnostic accuracy as FNA. Rodrigues-Pinto et al. [@JR664-33] reported higher malignancy detection with FNB than with FNA when the same number of passes was performed. According to a recent study [@JR664-37] examining the cost benefit analysis of ROSE in FNA, ROSE was advantageous when per-pass adequacy was low. In our estimate, we found no difference in diagnostic adequacy and diagnostic accuracy, but core needle biopsy required fewer passes to establish a diagnosis. This points towards the fact that the performance of the core biopsy needle may be superior to standard FNA.

Strengths and limitations
-------------------------

To our knowledge, this is the first meta-analysis comparing the diagnostic performance of two types of second generation core biopsy needles with standard FNA needles, and the first to specifically assess the influence of ROSE. Our meticulously conducted analysis included a comprehensive search strategy, with inclusion of the largest number of relevant studies, and adds substantially to the previously accumulated evidence. Due to the relatively higher number of studies in the analysis, we were able to assess for publication bias and conduct a predetermined meta-regression based on the presence or absence of onsite pathology; however, there are several limitations to our analysis. First, our estimates of diagnostic adequacy and number of passes required for diagnosis were limited by moderate and considerable heterogeneity. We evaluated the role of onsite pathology via meta-regression and found that it was a significant predictor of heterogeneity in diagnostic adequacy of pancreatic lesions and in mean number of passes required for diagnosis. Second, we could not perform a cost-benefit analysis from the included studies as such data were not reported. Third, the included studies mostly used 22G or 25G needles and data from the 19G needle was only included in one study. Finally, we have pooled the studies using ProCore and SharkCore needles together. All of these factors may have accounted for heterogeneity in our estimate.

How does this knowledge help our endoscopy practice? This meta-analysis does not establish superiority of core biopsy needles in comparison to standard FNA needles in terms of diagnostic adequacy, diagnostic accuracy, and optimal quality core procurement. However, in the absence of onsite cytopathological assessment, core biopsy needles showed a trend toward better diagnostic adequacy in all lesions, and significantly better diagnostic adequacy for pancreatic lesions. Also, core biopsy needles required a lower number of passes to establish the diagnosis.

In summary, this analysis of the literature adds considerable weight to the conclusion that FNB without ROSE can supplant EUS-FNA with ROSE without loss of diagnostic accuracy. The evolution of endosonographic tissue acquisition from FNA to FNB seems almost inevitable, as the elimination of ROSE not only makes the procedure more economical but it can also simultaneously provide qualitatively superior histologic specimens. Development of additional core needles for this purpose is in progress.
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